Vera Therapeutics Inc

VERA

25.470USD

+0.930+3.79%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

163 / 507

Overall Ranking

296 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

65.545

Target Price

+164.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 70.85.

Fairly Valued

The company’s latest PE is -6.84, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.82M shares, decreasing 3.98% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.41M shares of this stock.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -6.84, which is -21.47% below the recent high of -5.38 and -125.95% above the recent low of -15.47.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 163/507

No Data

The company’s current earnings forecast score is 8.15, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Vera Therapeutics Inc is 70.00, with a high of 100.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.15

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.19, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 26.17 and the support level at 22.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

-0.17

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 117.74%, representing a quarter-over-quarter increase of 3.12%. The largest institutional shareholder is PRFDX, holding a total of 4.41M shares, representing 6.92% of shares outstanding, with 1.33% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Avoro Capital Advisors LLC

5.70M

+1.64%

Longitude Capital Management Co., LLC

5.14M

--

T. Rowe Price Associates, Inc.

Star Investors

4.70M

+8.63%

BlackRock Institutional Trust Company, N.A.

3.59M

+0.96%

Kynam Capital Management LP

2.40M

+64.62%

Deerfield Management Company, L.P.

3.35M

+218.87%

Vestal Point Capital, LP

2.50M

+132.56%

The Vanguard Group, Inc.

Star Investors

2.91M

-1.06%

Fidelity Management & Research Company LLC

3.23M

+5.87%

Sofinnova Investments, Inc

2.79M

--



1

2



The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Vera Therapeutics Inc

VERA

5.20 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.85 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ACADIA Pharmaceuticals Inc

ACAD

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Zymeworks Inc

ZYME

7.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment